281 related articles for article (PubMed ID: 8952843)
1. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
3. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
4. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
5. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
6. Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep?
Stramba-Badiale M; Priori SG; Napolitano C; Locati EH; Viñolas X; Haverkamp W; Schulze-Bahr E; Goulene K; Schwartz PJ
Ital Heart J; 2000 May; 1(5):323-8. PubMed ID: 10832806
[TBL] [Abstract][Full Text] [Related]
7. [Molecular genetics in the hereditary form of long QT syndrome].
Georgijević Milić L
Med Pregl; 2000; 53(1-2):51-4. PubMed ID: 10953551
[TBL] [Abstract][Full Text] [Related]
8. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome.
Noda T; Takaki H; Kurita T; Suyama K; Nagaya N; Taguchi A; Aihara N; Kamakura S; Sunagawa K; Nakamura K; Ohe T; Horie M; Napolitano C; Towbin JA; Priori SG; Shimizu W
Eur Heart J; 2002 Jun; 23(12):975-83. PubMed ID: 12069453
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
10. Re-entrant cardiac arrhythmias in computational models of long QT myocardium.
Clayton RH; Bailey A; Biktashev VN; Holden AV
J Theor Biol; 2001 Jan; 208(2):215-25. PubMed ID: 11162065
[TBL] [Abstract][Full Text] [Related]
11. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
Shimizu W; Antzelevitch C
J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
[TBL] [Abstract][Full Text] [Related]
13. Effect of mexiletine on long QT syndrome model.
Wang HW; Zheng YQ; Yang ZF; Li CZ; Liu YM
Acta Pharmacol Sin; 2003 Apr; 24(4):316-20. PubMed ID: 12676070
[TBL] [Abstract][Full Text] [Related]
14. Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
Walker BD; Krahn AD; Klein GJ; Skanes AC; Yee R; Wang J; Hegele RA
Can J Cardiol; 2005 Jan; 21(1):33-8. PubMed ID: 15685300
[TBL] [Abstract][Full Text] [Related]
15. [Long QT syndrome].
Nakajima T; Kaneko Y; Taniguchi Y; Nagai R
Nihon Rinsho; 1996 Mar; 54(3):776-81. PubMed ID: 8904236
[TBL] [Abstract][Full Text] [Related]
16. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
[TBL] [Abstract][Full Text] [Related]
17. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Shimizu W; Antzelevitch C
Circulation; 1998 Nov; 98(21):2314-22. PubMed ID: 9826320
[TBL] [Abstract][Full Text] [Related]
18. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Yang Y; Lv TT; Li SY; Zhang P
J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3057-3067. PubMed ID: 34427958
[TBL] [Abstract][Full Text] [Related]
19. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
20. Heart rate dependence of the QT interval duration: differences among congenital long QT syndrome subtypes.
Nemec J; Buncová M; Bůlková V; Hejlik J; Winter B; Shen WK; Ackerman MJ
J Cardiovasc Electrophysiol; 2004 May; 15(5):550-6. PubMed ID: 15149424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
